ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 28 of 48
JMBS 2018, 3(2): 161–166
Fight against socially dangerous diseases

Pharmacoeconomic Evaluation of Standard Treatment Regimes of Tuberculosis Resistant to Isoniazid

Schevchenko O. S., Hovardovska O. O.

The article presents the study of pharmacoeconomic aspects of isoniazid-resistant tuberculosis. The literature review was conducted on this topic; the treatment results of patients that were registered in the Kharkiv region (Ukraine) with diagnosis of isoniazid-resistant tuberculosis, according to the results drug-sensitive test and treated by standard regimens were retrospectively studied. Cost-effectiveness analysis and modeling in the system "tree of solutions" were done. Materials and Methods. The retrospective study showed that in group treated by short-term regimen 65,9% were cured and in group treated by long-term regimen 77,7% got effective treatment. The cost of treatment is 1567 UAH and 3539 UAH, according to short-term and long-term regimens. The cost of treatment includes only funds for anti-tuberculosis drugs, does not include symptomatic and pathogenetic therapy, diagnostic methods, monitoring of treatment, etc. Indicator CER (cost-effectiveness ratio) for the short-term regimen is 23.78 UAH, and for the long-term regimen – 45.55 UAH. According to the pharmacoeconomic modeling, the difference in the cost is 2394 UAH, in the percentage long-term regime is more expensive than short-term by 51.6%. The results show that the short-term regimen prevails over the "cost-effectiveness" indicator, but the number of treatment failure after this regimen, which requires an extension of therapy, or the re-registration to the 4th category for the expansion of the Mycobacteria tuberculosis resistance spectrum, offset such benefits. Conclusions. As a result of the conducted pharmacoeconomic analysis it was set that among the charts of chemotherapy of advantage the chart of the Ministry of Health Care of Ukraine order № 1091. However, the amount of failures treatments on this chart in need for continuation of the appointed therapy for 9 more months, or translations in 4 categories on more valuable 20 months treatment, according to the results of drug sensitiveness test level such advantages. Modes of anti TB treatment taking into account their efficiency and financial viability must become the basis of modern phthisiatric practice. Perspectives for further research are direct and indirect charges on treatment of the tuberculosis caused by the different profiles of resistance to TB, for forming of adequate recommendations.

Keywords: tuberculosis, monoresistant tuberculosis, polyresistant tuberculosis, isoniazid-resistant tuberculosis, pharmacoeconomic modeling

Full text: PDF (Ukr) 246K

  1. Vorobev PA, Avksenteva MV, Borisenko OV, Vorobev AI, Vialkov DV, Lukiantceva DV, Sura MV, Iurev AS. Kliniko-ekonomicheskii analiz. Izdanie 3-e, dopolnennoe s prilozheniiami. M: Niudiamed, 2008. 778 s. [Russian]
  2. Kulikov AIu, Nguen TT, Tikhomirova AE. Metodologiia modelirovaniia v farmakoekonomike. Farmakoekonomika. 2011; 4 (4): 8-16. [Russian]
  3. Perelman MI, Bogadelnikova IV. Antibakterialnaia terapiia tuberkuleza legkikh. Uchebnoe posobie dlia studentov starshikh kursov, internov, klinicheskikh ordinatorov, vrachei. M.: Universum Pablishing, 1997. 80 s. [Russian]
  4. Petrenko VI, Todoriko LD, Hryshchuk LA, ta in. Ftyziatriya: nats pidruchnyk. Za red VI Petrenka. K: VSV «Medytsyna», 2015. 472 s. [Ukrainian]
  5. Nakaz MOZ Ukraine №620 vid 04.09.2014. Unifikovanyy klinichnyy protokol pervynnoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy doroslym. [Ukrainian]
  6. Nakaz MOZ Ukraine №1091 vid 21.12.2012. Pro zatverdzhennya ta vprovadzhennya medyko-tekhnolohichnykh dokumentiv zi standartyzatsiyi medychnoyi dopomohy pry tuberkul'ozi. [Ukrainian]
  7. Feshchenko YuI, Mel'nyk VM, Turchenko LV. Pohlyad na problemu borot'by z tuberkul'ozom v Ukraine. Ukrayins'kyy pul'monolohichnyy zhurnal. 2016; 3: 5-10. [Ukrainian]
  8. Feshchenko YuI, ta in. Osoblyvosti suchasnoyi sytuatsiyi z tuberkul'ozu v Ukraine. Ukrayins'kyy pul'monolohichnyy zhurnal. 2016; 1: 5-9. [Ukrainian].
  9. Bang D, Andersen PH, Andersen AB, Thomsen VØ. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission, and treatment outcome. J Infect. 2010 Jun; 60 (6): 452-7.
  10. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis. 2009; 48: 179–85.
  11. Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram M, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009; 373: 1183-9.
  12. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. European Respiratory Journal. 2014; 43: 554-65.
  13. Dorai Deepa, Shanta Achanta, Jyoti Jaju. The Impact of Isoniazid Resistance on the Treatment Outcomes of Smear Positive Re-Treatment Tuberculosis Patients in the State of Andhra Pradesh, India. PLoS One. 2013; 8 (10): e76189.
  14. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017 Feb; 17 (2): 223-34.
  15. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007–2009. Int J Tuberc Lung Dis. 2012 Jun; 16 (6): 812–6.
  16. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011 Aug; 53 (4): 369-72.
  17. Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Seong YL, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. BMC Infectious Diseases. 2008; 8: 6.
  18. Maguire H, Brailsford S, Carless J, Yates M, Altass L, Yates S, et al. Large outbreak of isoniazid-monoresistant tuberculosis in London, 1995 to 2006: Case-control study and recommendations. Euro Surveill. 2011; 16: pii 19830.
  19. WHO Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization. Geneva, 2014. 447 p.